- 29 Downloads
Zotepine is an atypical antipsychotic with high affinity for serotonin 5- HT2A and 5- HT2C and dopamine D2, D3, D1 and D4.2 receptors and is a potent inhibitor of reuptake of nor adrenaline (norepinephrine). The major metabolite of zotepine, norzotepine is pharmacologically active and possesses affinity for dopaminergic receptors similar to the parent compound. Pharmacodynamic data suggest that at low doses the drug increases dopaminergic neurotransmission, while at higher doses it acts as a dopaminergic receptor antagonist.
In double- blind trials zotepine 150 to 300 mg/day was as effective as typical antipsychotics such as haloperidol, chlorpromazine, perazine and thiothixene in controlling symptoms of schizophrenia. Although improvement occurred with both zotepine and haloperidol in patients with predominantly negative schizophrenic symptoms, only zotepine achieved significant reductions in most individual negative symptom scores versus baseline. Results from 1 study suggest that maintenance therapy with zotepine for up to 1 year was effective in preventing relapse in schizophrenic patients. In 2 trials in patients with treatment- resistant schizophrenia, some improvement occurred in most patients after the initiation of zotepine either in place of previous drugs or as add- on therapy.
Zotepine is generally well tolerated; constipation, dry mouth, insomnia, sleepiness, asthenia and bodyweight gain are the commonly encountered adverse effects. The incidence of extrapyramidal symptoms with zotepine is low (8 to 29%) and significantly less than that seen with haloperidol and chlorpromazine; however, there were no differences between zotepine and some other typical antipsychotics in this respect. Dosages ≥ 300 mg/day are associated with an increased risk of generalised convulsions.
Thus, zotepine is as effective as typical antipsychotic agents in the management of acute exacerbations of schizophrenia and may be useful for the prevention of relapse. Initial trials have found the drug to be effective in the management of patients with negative schizophrenic symptoms and those with treatment- resistant schizophrenia.
Zotepine is a dibenzothiepine tricyclic antipsychotic agent which has high affinity for serotonin 5-HT2A and 5-HT2C receptors and dopamine D2, D3, D1 and D4.2 receptors. Norzotepine, the major metabolite of zotepine in humans and animals, is pharmacologically active and shows affinity for dopaminergic receptors which is similar to that of zotepine. In rats and mice, zotepine potently inhibited noradrenaline (norepinephrine) reuptake. In addition to showing central antidopaminergic and antiserotonergic activities in animal models, zotepine was as effective as haloperidol and more effective than clozapine in inhibiting N-methyl D-aspartate glutamate receptor antagonist—induced animal behaviours.
Administration of zotepine in animals revealed a dichotomic effect on dopaminergic receptors; at low doses zotepine increases dopaminergic activity, while at higher doses it has an inhibitory effect on dopaminergic neurotransmission. There was improvement in cognitive dysfunction in 13 patients treated with zotepine (150 to 450 mg/day) over 6 weeks. Administration of zotepine 150 to 250 mg/day for 4 weeks did not significantly affect thyroid function tests, although blood thyroxine levels tended to decrease from pretreatment values.
Data on the pharmacokinetics of zotepine in humans are limited consequently animal data have been included where necessary for completeness. There is almost complete absorption of zotepine after oral administration in animals. Plasma concentrations of zotepine peaked at approximately 13 to 31 μg/L about 3 hours after a single oral dose of zotepine 50mg in healthy volunteers. Most of the drug is metabolised by the liver and only 0.03 to 0.07% of the drug is excreted unchanged in urine. There appears to be some degree of enterohepatic circulation. The elimination half-life of zotepine ranges from about 15 to 24 hours. Zotepine plasma concentrations are elevated in the elderly and in patients receiving concomitant benzodiazepines but not anticholinergic drugs.
In double-blind comparative trials, zotepine was as effective as typical antipsychotic agents in the management of patients with positive and negative schizophrenic symptoms. There are no trials comparing the efficacy and tolerability of zotepine with those of other atypical antipsychotics such as risperidone, quetiapine or amisulpiride in patients with schizophrenia.
Administered in a double-blind fashion, zotepine (150 to 300 mg/day) was as effective as haloperidol (6 to 20 mg/day) in improving schizophrenic symptoms. In other double-blind trials the efficacy of zotepine was similar to that of chlorpromazine, perazine and thiothixene.
Zotepine was also effective in treating patients with predominantly negative schizophrenic symptoms in noncomparative and comparative studies. One 7-week, double-blind, randomised trial reported significant improvements over baseline in 4 of 5 negative schizophrenic symptoms with zotepine (50 to 150 mg/day) but not with haloperidol (2 to 6 mg/day). Zotepine (106 to 396 mg/day) was as effective as perazine (214 to 575 mg/day) in treating patients with negative schizophrenic symptoms.
In a multicentre trial, administration of zotepine (up to ≈300 mg/day), alone or in combination with other drugs, was associated with significant improvement in 29 of 35 patients with treatment-resistant schizophrenia. The administration of zotepine 50 to 500 mg/day for 1 to 36 months (mean 12 months) lead to a moderate to marked improvement in the overall severity of disease in 17 of 22 patients with treatment resistant schizophrenia.
A placebo-controlled, double-blind study in 121 patients with schizophrenia with a recent history of relapse found zotepine (150 to 300 mg/day) to be significantly better than placebo in preventing relapse over 26 weeks.
Randomised, double-blind comparative studies have reported a significantly lower incidence of extrapyramidal symptoms (EPS) with zotepine (8 to 29%) than with haloperidol and chlorpromazine. However, the incidence of EPS with zotepine was similar to that seen with perazine and thiothixene.
At the dosage used to manage schizophrenic patients zotepine was generally well tolerated. Adverse events seen in zotepine recipients include insomnia, reduced salivation, sleepiness, constipation, asthenia and bodyweight gain (individual incidence 10 to 39%). Aretrospective review of 110 schizophrenic patients found significantly greater bodyweight gain in patients treated with zotepine than in those treated with typical antipsychotics for ≥2 weeks (3.6 vs 1.3kg). An increase in the risk of generalised convulsions has been observed with zotepine at dosages >300 mg/day (above the maximum recommended dosage for nonsevere disease), especially if being administered in combination with other antipsychotic agents. Monitoring of tolerability of zotepine is recommended in the elderly. No clinically relevant haematological abnormalities have been reported to date.
Dosage and Administration
Zotepine should be initiated at total daily doses of 75 to 150mg in 3 divided doses. Based on the clinical response the daily dose may be gradually increased up to 300mg. In severely ill, hospitalised patients 450 mg/day may be used. Monitoring of EEG is recommended in patients receiving zotepine >300 mg/day concurrently with other antipsychotic agents.
KeywordsSchizophrenia Adis International Limited Haloperidol Clozapine Negative Symptom
Unable to display preview. Download preview PDF.
- 2.Fujiwara Y, Harada T, Otsuki S. Double-blind comparative study of zotepine and lithium carbonate on mania [abstract]. Neuropsychopharmacology 1994 May; 10 Suppl. (Pt 2): 40Google Scholar
- 6.Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996 Mar; 124: 57–73Google Scholar
- 8.Heal DJ, Needham PL. Comparison of the pharmacological profiles of zotepine and norzotepine [abstract]. Eur Neuropsychopharmacol 1996 Jun; 6Suppl. 3: 105Google Scholar
- 10.Leysen JE, Schotte A, Janssen PFM, et al. Interaction of new antipsychotics with neurotransmitter receptors in vitro and in vivo: pharmacological to therapeutic evidence. In: Fog R, Gerlach J, Hemmingsen R, editors. Schizophrenia, an integrated view. Munksgaard, Copenhagen: Alfred Benson Symposium, 1995: 344–60Google Scholar
- 12.Needham PL, Atkinson J, Cheetham SC, et al.Binding of zotepine, clozapine and haloperidol to 5-HT receptor subtypes [abstract]. Br J Pharmacol 1996 Apr; 117 Proc. Suppl.: 140PGoogle Scholar
- 14.Needham PL, Skill MJ, Cheetham SC, et al. Zotepine: preclinical support for antidepressant activity. Nottingham: Knoll Pharmaceuticals Research and Development. (Data on file)Google Scholar
- 17.Lai H, Carino MA, Sperry R, et al. Effects of microinjection of 2-chloro-11 (2-dimethylaminoethoxy)-dibenzo[b,f]-thiepine (zotepine), thioridazine and haloperidol into the striatum and nucleus accumbens on Stereotypic behaviour and motor activity. J Pharm Pharmacol 1981 Apr; 33: 252–4PubMedGoogle Scholar
- 24.Rowley HL, Kilpatrick IC, Needham PL, et al. The atypical antipsychotic, zotepine, elevates extracellular noradrenaline in the frontal cortex of freely-moving rats. Nottingham: Knoll Pharmaceuticals Research and Development. (Data on file)Google Scholar
- 27.Martin JB, Reichlin S. Regulation of prolactin secretion and its disorders. In: Martin JB, Reichlin S, editors. Clinical neuroendocrinology. 2nd ed. Philadelphia: F.A. Davis Company, 1987: 201–31Google Scholar
- 28.Otani K, Kondo T, Ishida M, et al. Prolactin response to zotepine in schizophrenic patients. Hum Psychopharmacology 1993 Jan–Feb; 8: 35–9Google Scholar
- 30.König F, Wolfersdorf M, Kaschka WP. Changes of thyroid parameters during therapy with zotepine — preliminary results [abstract no. 65–105]. Biol Psychiatry 1997; 42 Suppl.: 182SGoogle Scholar
- 34.Velagapudi R, Faulkner R, Hinson JL, et al. The effect of age on the pharmacokinetics of zotepine and its metabolite norzotepine in healthy volunteers. Biol Psychiatry 1997; 42 Suppl.: 46SGoogle Scholar
- 35.Tanaka O, Kondo T, Kaneko S, et al. A method for rapid determination of zotepine by gas chromatography-mass spectrometry. Ther Drug Monit 1996 Jun; 16: 294–6Google Scholar
- 36.Otani K, Kondo T, Kaneko S, et al. Steady-state serum kinetics of zotepine. Hum Psychopharmacology 1992 Sep–Oct; 7: 331–6Google Scholar
- 37.Kondo T, Otani K, Ishida M, et al. A study of the therapeutic spectrum of a fixed-dose of zotepine and its relationship with serum concentrations of the drug. Hum Psychopharmacology 1993 Mar–Apr; 8: 133–9Google Scholar
- 38.Turton RW, McCormick DJ, Hopper JB, et al. Metabolism of zotepine by man and animals [abstract]. Eur Neuropsychopharmacol 1997; 7Suppl. 2: S221Google Scholar
- 39.Turton RW, McCormick DJ, Hopper JB, et al. Metabolism of zotepine by animals and man. Nottingham: Knoll Pharmaceuticals, Pennyfoot Street Campus. (Data on file)Google Scholar
- 40.McCormick DJ, Stewart T, Vowles DT. In vitro investigations of drug-drug interactions with zotepine at CYP450 [abstract no. 65-57]. Biol Psychiatry 1997; 42 Suppl.: 174SGoogle Scholar
- 42.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington DC: The American Psychiatric Association, 1980Google Scholar
- 43.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington DC: The American Psychiatric Association, 1987Google Scholar
- 44.Degwitz R, Helmchen H, Kokott G, et al. Diagnosen-schlussel und Glossar psychiatrischer Krankheiten. 9. Rev.,5. Aufl. ed. Barlin: Springer Verlag, 1980Google Scholar
- 45.Klieser E, Lehmann E, Lemmer W, et al. Experimental comparison of the efficacy and tolerance of zotepine and haloperidol in acute schizophrenia [abstract]. Pharmacopsychiatry 1992 Mar; 25: 107Google Scholar
- 46.Nishizono M. A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients [abstract]. Neuropsychopharmacology 1994 May; 10 Suppl. (Pt 2): 30Google Scholar
- 47.Cooper SJ, Raniwalla J, Welch C. Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo [abstract]. Eur Neuropsychopharmacol 1996 Jun; 6Suppl. 3: 148Google Scholar
- 48.Kilpatrick AT, Welch CP, Butler A, et al. The efficacy of zotepine in reducing BPRS total score [abstract]. Eur Neuropsychopharmacol 1997; 7Suppl. 2: S205Google Scholar
- 55.Dieterle DM, Müller-Spahn F, Ackenheil M. Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics [in German]. Fortschr Neural Psychiatr 1991 Sep; 59Suppl. 1: 18–22Google Scholar
- 64.Dieterle DM, Ackenheil M, Kapfhammer HP, et al. The effect of zotepine on productive and negative symptoms in schizophrenic patients. Psychiatr Psychobiol 1988; 3(2): 125–30Google Scholar
- 65.Welch CP, Kilpatrick AT, Butler A, et al. The efficacy of zotepine in reducing negative symptoms [abstract]. Eur Neuropsychopharmacology 1997; 7 Suppl. 2: S213Google Scholar
- 66.Davies JM, Schaffer CB, Killman GA, et al. Important issues in the treatment of schizophrenia. Schizophr Bull 1980; 6: 70–87Google Scholar
- 70.Cooper SJ, Butler A, Tweed J, et al. Zotepine in prevention of relapse [abstract no. 14–110]. Biol Psychiatry 1997 July; 42 Suppl.: 41SGoogle Scholar
- 71.Palmgren K, Tweed JA, Welch CP, et al. A multicentre naturalistic long term study of zotepine. European Congress of the World Psychiatric Association (WPAEC); Geneva, 1997 Apr 23–26Google Scholar
- 72.Casey DE, Keepers GA. Neuroleptic side effects: acute extra-pyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV, editors. Psychopharmacology: current trends. Berlin: Springer, 1988: 74–93Google Scholar
- 75.Hummer M, Fleischhacker WW. Compliance and outcome in patients treated with antipsychotics: the impact of extra-pyramidal syndromes. CNS Drugs 1996; 5Suppl. 1: 13–20Google Scholar
- 79.Cooper SJ, Welch CP. A comparison of zotepine and chlorpromazine on BPRS subscores [abstract]. Eur Neuropsychopharmacol 1997; 7Suppl. 2: S225–6Google Scholar
- 80.Lingjærde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 76Suppl. 334: 1–100Google Scholar
- 83.Yamawaki S, Yano E, Uchitomi Y. Analysis of 497 cases of neuroleptic malignant syndrome in Japan. Hiroshima J Anesth 1990; 26(1): 35–44Google Scholar
- 84.Tanaka O, Otani K, Kondo T, et al. Paralytic ileus as a prodromal symptom of the neuroleptic malignant syndrome. Hum Psychopharmacology 1993; 8(5): 367–9Google Scholar
- 85.Lomas J, Boardman RH, Markowe M. Complications of chlorpromazine therapy in 800 mental-hospital patients. Lancet 1955; I: 1144–7Google Scholar
- 89.Davies RK, Neil JF, Himmelhoch JM. Cerebral dysrhythmias in schizophrenics receiving phenothiazines: clinical correlates. Clin Electroencephalogr 1975; 6: 103–25Google Scholar
- 90.Kugler J, Lorenzi E, Spatz R, et al. Drug-induced paroxysmal EEG activities. Pharmacopsychiatr Neuropsychopharmakol 1979; 12: 165–72Google Scholar
- 91.Schlichter W, Bristow ME, Schultz S, et al. Seizures occurring during intensive chlorpromazine therapy. Can Med Assoc J 1956; 74: 364–6Google Scholar
- 92.Tsuchiya H, Kawahara R, Tanaka Y, et al. Generalized seizure during treatment of schizophrenia with zotepine. Yonago Acta Med 1986; 29(2): 103–11Google Scholar
- 94.Manmaru S. Five cases of schizophrenia with convulsive seizures during zotepine administration [in Japanese]. Seishin Igaku 1985; 27: 59–70Google Scholar
- 95.Reynolds C, Kilpatrick AT, Bratty R. Zotepine, a broad spectrum antipsychotic with low extrapyramidal side effects [abstract]. Eur Neuropsychopharmacol 1997; 7Suppl. 2: S225Google Scholar
- 97.Edwards IR. Pharmacological basis of adverse drug reactions. In: Speight TM, Holford NHG, editors. Avery’s drug treatment. 4th ed. Auckland: Adis International Ltd, 1997: 261–99Google Scholar
- 101.Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society of Great Britain: The Pharmaceutical Press, 1996Google Scholar
- 102.Kammer-Reusch M, editor. Gelbe Liste Pharmindex. 2 Quartal ed. Neu Isenburg, GmbH: MediMedia. Medizinische Medien Informations, 1997Google Scholar
- 103.Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatry Bull 1990; 14: 522–5Google Scholar
- 104.Seeman P. Brain dopamine receptors. Pharmacol Rev 1980; 32: 197–202Google Scholar
- 105.Seiden L, Sabol K. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993; 32: 639–77Google Scholar
- 106.Csernansky JG, Brown K, Hollister LE. Is there drug treatment for negative schizophrenic symptoms? Hosp Formul 1986; 21: 790–2Google Scholar
- 112.Green JF, King DJ. Cognitive functioning in schizophrenia: effects of drug treatments. CNS Drugs 1996 Nov; 6: 382–98Google Scholar
- 113.Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical anti-psychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6Suppl. 2: S2–13–S2–20Google Scholar
- 114.Gallhofer B, Bauer U, Gruppe H, et al. First episode schizophrenia: the importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 1996; 2: 16–24Google Scholar